Key Points
- Director Luke Evnin sold a total of 487,848 Werewolf Therapeutics shares between Nov 3–17 for roughly $551,000 (including 58,372 shares on Nov 13 at an average $0.98); he still holds 3,592,061 shares after the Nov. 13 filing, a 1.6% reduction in his position.
- HOWL shares trade around $0.92 with a 12‑month range of $0.60–$2.38 and a market cap of about $44.6M, while analysts' consensus is a "Moderate Buy" with an average price target of $8.00.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 36,621 shares of the company's stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $0.95, for a total value of $34,789.95. Following the transaction, the director directly owned 3,515,880 shares in the company, valued at approximately $3,340,086. This trade represents a 1.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Luke Evnin also recently made the following trade(s):
- On Friday, November 14th, Luke Evnin sold 39,560 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.93, for a total value of $36,790.80.
- On Thursday, November 13th, Luke Evnin sold 58,372 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total value of $57,204.56.
- On Wednesday, November 12th, Luke Evnin sold 26,101 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.09, for a total value of $28,450.09.
- On Tuesday, November 11th, Luke Evnin sold 35,818 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.14, for a total transaction of $40,832.52.
- On Monday, November 10th, Luke Evnin sold 31,172 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.18, for a total transaction of $36,782.96.
- On Friday, November 7th, Luke Evnin sold 43,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.11, for a total transaction of $48,784.50.
- On Thursday, November 6th, Luke Evnin sold 34,947 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.21, for a total transaction of $42,285.87.
- On Wednesday, November 5th, Luke Evnin sold 30,774 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.22, for a total transaction of $37,544.28.
- On Tuesday, November 4th, Luke Evnin sold 90,164 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total transaction of $110,000.08.
- On Monday, November 3rd, Luke Evnin sold 60,369 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.29, for a total transaction of $77,876.01.
Werewolf Therapeutics Price Performance
HOWL stock opened at $0.92 on Tuesday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. The business has a 50-day simple moving average of $1.57 and a two-hundred day simple moving average of $1.34. The company has a market capitalization of $44.63 million, a P/E ratio of -0.57 and a beta of 0.73. Werewolf Therapeutics, Inc. has a 52-week low of $0.60 and a 52-week high of $2.38.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.03. Research analysts expect that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several brokerages have weighed in on HOWL. JMP Securities dropped their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 21st. Zacks Research upgraded shares of Werewolf Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Thursday, October 16th. Bank of America reduced their price objective on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a "buy" rating for the company in a research report on Monday, August 25th. Citigroup reiterated a "market outperform" rating on shares of Werewolf Therapeutics in a research note on Wednesday, November 12th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Werewolf Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $8.00.
Get Our Latest Stock Report on HOWL
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Quadrature Capital Ltd purchased a new stake in Werewolf Therapeutics in the 2nd quarter worth about $28,000. Qube Research & Technologies Ltd bought a new position in Werewolf Therapeutics during the second quarter worth about $48,000. Nuveen LLC purchased a new position in shares of Werewolf Therapeutics in the first quarter worth about $71,000. AQR Capital Management LLC purchased a new position in shares of Werewolf Therapeutics in the first quarter worth about $79,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $92,000. Institutional investors own 64.84% of the company's stock.
About Werewolf Therapeutics
(
Get Free Report)
Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
